{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XRZC83NT/ef11b5ae-d3b5-4eac-832b-c60c49471ba7/PDF","dcterms:extent":"293 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-XRZC83NT/7caa407a-fce9-4778-9ef8-aa9e5cbe7152/TEXT","dcterms:extent":"26 KB"}],"edm:TimeSpan":{"@rdf:about":"2008-2026","edm:begin":{"@xml:lang":"en","#text":"2008"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-XRZC83NT","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-YR600LYC"},{"@xml:lang":"sl","#text":"Acta medico-biotechnica"}],"dcterms:issued":"2026","dc:creator":["Forštnarič, Alex","Piko, Nejc","Stajan, Ana"],"dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:19"},{"@xml:lang":"sl","#text":"str. 10-17"}],"dc:identifier":["DOI:10.18690/actabiomed.300","ISSN:1855-5640","COBISSID_HOST:282354179","URN:URN:NBN:SI:doc-XRZC83NT"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Univerzitetna založba Univerze v Mariboru"},"dc:subject":[{"@xml:lang":"en","#text":"botulinum toxin type A"},{"@xml:lang":"en","#text":"chronic kidney disease"},{"@xml:lang":"en","#text":"clinical outcomes"},{"@xml:lang":"en","#text":"heart failure"},{"@xml:lang":"sl","#text":"klinični izidi"},{"@xml:lang":"sl","#text":"kronična ledvična bolezen"},{"@xml:lang":"en","#text":"SGLT2 inhibitors"},{"@xml:lang":"sl","#text":"SGLT-2 zaviralci"},{"@xml:lang":"sl","#text":"sladkorna bolezen tipa 2"},{"@xml:lang":"sl","#text":"srčno popuščanje"},{"@xml:lang":"en","#text":"type 2 diabetes"}],"dcterms:temporal":{"@rdf:resource":"2008-2026"},"dc:title":{"@xml:lang":"sl","#text":"Koristi in pasti zdravljenja s SGLT-2 zaviralci| Balancing the benefits and risks of SGLT2 Inhibitors|"},"dc:description":{"@xml:lang":"sl","#text":"Uradna znanstveno raziskovalna strokovna revija Medicinske fakultete Univerze v Mariboru z naslovom Acta medico-biotehnica, izhaja najmanj dvakrat letno od leta 2008, ima tudi spletno izdajo. "},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-XRZC83NT","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-XRZC83NT"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-XRZC83NT/ef11b5ae-d3b5-4eac-832b-c60c49471ba7/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Univerza v Mariboru, Medicinska fakulteta"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-XRZC83NT/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-XRZC83NT"}}}}